Allakos

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

benzinga_deal_dispatch2

Global

ALLK

BIIB

CSCO

JNPR

MSFT

ORCL

RBLX

SAGE

SMIN

TYO:5401

TYO:5481

ULCC

WELL

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok

Biotech

News

Health Care

Movers

Trading Ideas

General

Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 million in estimated costs.

Why Is Allakos Stock Plunging On Monday?

S&P 500

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

AKRO

DADA

ELAB

VERU

S&amp;P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher

Allakos Inc

Allkem Ltd

Press Releases

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

Analyst Ratings

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results

Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

Legal

Management

Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

Abpro Hldgs

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

BioVie

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Celularity

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Curis

CEL-SCI

Cyclo Therapeutics

Elevation Oncology

Equillium

IN8bio

Longeveron

Lisata Therapeutics

Nanoviricides

NextCure

Passage Bio

Palatin Techs

Q32 Bio

Rallybio

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Tenax Therapeutics

Unity Biotechnology

Exicure

JMP Securities

Jefferies

Barclays

Piper Sandler

Comments

Allakos

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga